Osteoarthritis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PI3K 0
• NRF2 0
• NLRP3 0
• MAPK 0
• AMPK 1
• GLP-1 3
• IL-1 1
• AKT 0
• mTOR 0
• STAT3 0
• SIRT1 0
• TLR4 0
• JAK 0
• COX-2 0
• ERK 0
• CTNNB1 0
• IL-6 0
• PPAR 0
• STING 0
• TP53 0
• GPX4 0
• HIF-1 0
• JNK 0
• TNF 0
• YAP 0
• PINK1 0
• PTEN 0
• VEGF 0
• IL-17 0
• METTL3 0
• RANKL 0
• EGFR 0
• BCL-2 0
• CXCR4 0
• FTO 0
• HMGB1 0
• MMP-9 0
• SGLT2 1
• CGRP 0
• FGFR 0
• HDAC 0
• KEAP1 0
• MDM2 0
• PARP 0
• APOE 0
• BRD4 0
• CDK4/6 0
• ESR1 0
• FAK 0
• GIP 0
• HER2 0
• HSP90 0
• MEK 0
• NMDA 0
• TREM2 0
• APP 0
• AR 0
• ARID1A 0
• CD47 0
• CFTR 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIA · F30

  Dissecting Age-related Changes in Stem Cell-based Bone-Gut Crosstalk

  University of California at Davis· Davis, United States· US$43,752 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, United States· US$350,188 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R56

  Understanding the Roles of Synovitis, Knee-Adjacent Obesity and Sarcopenia in Pain Phenotypes and Structural Progression of Knee Osteoarthritis - An Analysis of the Entire Osteoarthritis Initiative

  University of California, San Francisco· San Francisco, United States· US$620,656 awarded in fiscal year 2026· until Aug 2027

• NIH NIAMS · R01

  Fe Metabolism Compromises Articular Chondrocytes during Joint Degeneration

  University of Iowa· Iowa City, United States· US$660,873 awarded in fiscal year 2026· until Aug 2031

• NIH NIDCR · R43

  SN102: a Novel Gene Therapy for Trigeminal Neuralgia Pain

  Sereneuro Therapeutics, Inc.· Baltimore, United States· US$338,115 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Biofabrication of gene activated grafts targeting synovial joint inflammation and meniscus repair (SMART-MENISCUS)

  The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin· Dublin, Ireland· EU contribution €1,500,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  EV-enriched secretome from cord blood as a new disease modifying treatment for osteoarthritis (ExoCordOA)

  Exogenus Therapeutics Sa· Cantanhede, Portugal· EU contribution €13,000,000· until Aug 2031· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Smart Platforms for Osteochondral Regeneration through on-demand Activation (SPORA)

  Instituto Superior Tecnico· Lisboa, Portugal· EU contribution €191,343· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Newly engineered lignin nanocarrier for curcumin delivery to tackle inflammation and limited synovial drug residence in osteoarthritis (LigNPsCURCDeLIV)

  University of Leeds· Leeds, United Kingdom· EU contribution €276,188· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Gene-activated tri-layer 3D-bioprinted scaffold for enhanced osteochondral defect repair (GATSO-3D)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €252,729· until Jul 2028

  The disease is named only in the funder's project summary, not in the title.

10 of 421 running projects, newest first. Listed amounts together: US$229.9m + €106.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis

  NCT05276895· Assiut University· Updated 25 Jul 2023

  “unavailability of drugs”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

  NCT04886258· Novartis Pharmaceuticals· Source

• Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis

  NCT05276895· Assiut University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 43
• Organoids 4
• Mendelian Randomization Analysis 56
• CRISPR-Cas Systems 1
• Gene Expression Profiling 106
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 43
• Metabolomics 26
• Mass Spectrometry 5
• Flow Cytometry 7
• Immunohistochemistry 19
• Positron-Emission Tomography 6
• Magnetic Resonance Imaging 276
• Machine Learning 78
• Deep Learning 45
• Cohort Studies 148
• Genome-Wide Association Study 48

• Mapping articular cartilage maturation across postnatal development by proteomics.

  Osteoarthritis Cartilage, Jun 2026

• Mass Spectrometry-Based Screening Reveals Inhibitors of Cholesterol 25-Hydroxylase.

  ACS Chem Biol, Jun 2026

• Tissue and extracellular matrix remodeling of the subchondral bone during osteoarthritis of knee joints as revealed by spatial mass spectrometry imaging.

  Bone Res, Jan 2026

• Rapid Detection of Adulteration in Boswellia Extracts with Citric Acid by UPLC-HRMS and 1H NMR.

  J Diet Suppl, Jan 2024

• Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (Cavia porcellus).

  J Vet Pharmacol Ther, Oct 2021

See which targets of this disease your abstract mentions, and go to the people working on them.